To date we have developed a FHI TCD Consortium of five clinical sites, four processing centers, and cores in donor chimerism, anti-HLA antibodies, immunology, cell processing, biostatistics, neuroimaging, neurocognition, quality of life, pulmonary function, pulmonary vascular, radiation therapy, and a patient advocacy group.
Sickle Cell Disease and
Stem Cell Transplantation
Sickle cell disease (SCD) is a genetic disorder that primarily affects those of African descent and Hispanics of Caribbean ancestry, and can also be found in those with Middle Eastern, Indian, Latin American, Native American and Mediterranean heritage. It has been estimated that 75-85,000 people in the US are affected by the disease. Millions worldwide suffer complications from sickle cell disease. SCD is characterized by chronic vaso-occlusive complications, multiple organ dysfunction, and premature death. Current therapies for SCD include supportive care with penicillin, vaccination and narcotics, chronic transfusion, and/or hydroxyurea.
The only curative therapy for SCD is Myeloablative (MA) Allogeneic Stem Cell Transplantation (AlloSCT) from an unaffected HLA matched sibling donor. However, only approximately 15% of SCD patients have such donors. An alternate allogeneic donor source includes unaffected familial haploidentical (FHI) donors. The Haplo SCD Consortium was developed to provide resources to families, patients, and physicians pursuing FHI transplantation for SCD.
For more information about the Haplo Sickle Cell Disease Consortium or the open protocol specifically please contact:
Mitchell Cairo, MD, Principal Investigator
Erin Morris, RN, Study Coordinator